Table 1.

Patient Characteristics and Types of Data Used in 10 Study Sets.^*

Study Set	No. of Patients	No. with Matched DNA from Non-neoplastic Tissue	Sex	Age(yr)	Vital Status	Median Weeks of Follow-up (Range)	Data Type†	Source
1	219‡	91	Female: 77 Male: 130	55.8±15.1	Dead: 192 Alive: 15	50.6 (1.1–503.4)	G, E, C	Cancer Genome Atlas Project
2	182	0	NA	NA	NA	NA	G	REMBRANDT release 1.5.4.1
3	46	0	NA	NA	NA	NA	G	REMBRANDT release 1.5.3
4	36	0	NA	NA	NA	NA	G	Northwestern University
5	32	0	NA	NA	NA	NA	S	Stanford University
6	15	0	NA	NA	NA	NA	S	Barrow Neurological Institute
7	49§	0	Female: 15 Male: 34	49.9±12.1	Dead: 46 Alive: 3	70.0 (3.0–313.0)	E, C	M.D. Anderson Cancer Center (GEO accession no., GSE4271)
8	47	0	Female: 25 Male: 22	50.5±15.6	Dead: 34 Alive: 13	42.0 (1.0–178.0)	E, C	University of California, Los Angeles (GEO accession no., GSE4412)
9	191	0	Female: 74 Male: 117	53.8±13.6	Dead: 176 Alive: 15	55.6 (1.0–479.0)	E, C	Multi-institutional (GEO accession no., GSE13041)
10	76	0	Female: 21 Male: 55	51.1±9.1	Dead: 63 Alive: 13	66.9 (6.1–311.9)	E, M, C	Phase 2 trial, EORTC-NCIC phase 3 trial (GEO accession no., GSE7696)¶

^*Plus–minus values are means ± SD. GEO denotes Gene Expression Omnibus, and NA not available.

^†The types of data include clinical-outcome data (C), gene-expression data (E), gene copy number data (G), methylation status of the MGMT promoter (M), and sequencing data (S).

^‡There were 219 patients in study set 1; clinical data were available for 207 of those patients.

^§Twenty-two patients had matched tumor pairs from the initial diagnosis and recurrent disease; therefore, 71 tumors were assessed in study set 7.

^¶ Study set 10 included 76 patients with glioblastoma who were treated as part of a phase 2 trial or a European Organization for Research and Treatment of Cancer (EORTC)/National Cancer Institute of Canada (NCIC) randomized phase 3 trial (22981-26981/CE.38), both of which evaluated the addition of concomitant and adjuvant temozolomide to radiotherapy.^31,32